JP2024532705A5 - - Google Patents
Info
- Publication number
- JP2024532705A5 JP2024532705A5 JP2024506734A JP2024506734A JP2024532705A5 JP 2024532705 A5 JP2024532705 A5 JP 2024532705A5 JP 2024506734 A JP2024506734 A JP 2024506734A JP 2024506734 A JP2024506734 A JP 2024506734A JP 2024532705 A5 JP2024532705 A5 JP 2024532705A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- cells
- myeloid cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL285416 | 2021-08-05 | ||
| IL285416A IL285416A (en) | 2021-08-05 | 2021-08-05 | Antibodies for cancer treatment |
| PCT/IL2022/050849 WO2023012802A1 (en) | 2021-08-05 | 2022-08-04 | Antibodies for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532705A JP2024532705A (ja) | 2024-09-10 |
| JP2024532705A5 true JP2024532705A5 (https=) | 2025-08-04 |
Family
ID=83004541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024506734A Pending JP2024532705A (ja) | 2021-08-05 | 2022-08-04 | 癌を治療するための抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240239886A1 (https=) |
| EP (1) | EP4380975A1 (https=) |
| JP (1) | JP2024532705A (https=) |
| CN (1) | CN118076643A (https=) |
| CA (1) | CA3226996A1 (https=) |
| IL (2) | IL285416A (https=) |
| WO (1) | WO2023012802A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024206738A1 (en) | 2023-03-31 | 2024-10-03 | Immunai Inc. | Humanized anti-trem2 antibodies |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| KR20260047599A (ko) * | 2023-08-30 | 2026-04-08 | 데이진 화-마 가부시키가이샤 | 신경 변성 질환의 치료제 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005022928D1 (de) * | 2004-11-30 | 2010-09-23 | Abgenix Inc | Antikörper gegen gpnmb und ihre verwendungen |
| US20130156784A1 (en) * | 2008-08-20 | 2013-06-20 | Michael Jeffers | Compositions Using Antibodies Directed To GPNMB And Uses Thereof |
| EP2453919A1 (en) * | 2009-05-20 | 2012-05-23 | Celldex Therapeutics, Inc. | Antibodies directed to gpnmb and uses thereof |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| US20190330335A1 (en) * | 2015-10-06 | 2019-10-31 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| AU2018383709B2 (en) * | 2017-12-12 | 2025-09-11 | Pionyr Immunotherapeutics, Inc. | Anti-TREM2 antibodies and related methods |
| KR20210104079A (ko) * | 2018-12-11 | 2021-08-24 | 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 | 항-trem2 항체를 사용하는 방법 |
| KR102239781B1 (ko) * | 2019-04-08 | 2021-04-13 | 주식회사 녹십자 | Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도 |
| IL272390A (en) * | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
-
2021
- 2021-08-05 IL IL285416A patent/IL285416A/en unknown
-
2022
- 2022-08-04 EP EP22757699.8A patent/EP4380975A1/en active Pending
- 2022-08-04 JP JP2024506734A patent/JP2024532705A/ja active Pending
- 2022-08-04 WO PCT/IL2022/050849 patent/WO2023012802A1/en not_active Ceased
- 2022-08-04 IL IL310605A patent/IL310605A/en unknown
- 2022-08-04 CN CN202280065311.9A patent/CN118076643A/zh active Pending
- 2022-08-04 CA CA3226996A patent/CA3226996A1/en active Pending
-
2024
- 2024-02-05 US US18/432,214 patent/US20240239886A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024532705A5 (https=) | ||
| AU2020270555B2 (en) | Combination therapy with an anti BCMA antibody and a gamma secretase inhibitor | |
| JP2022061992A5 (https=) | ||
| JP2025016606A5 (https=) | ||
| EP4588940A3 (en) | Antibody-drug conjugate comprising antibody against human ror1, and use for the same | |
| JP2022502051A5 (https=) | ||
| RU2747735C3 (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2012504955A5 (https=) | ||
| JP2021527640A5 (https=) | ||
| JP2006512899A5 (https=) | ||
| JP2009511480A5 (https=) | ||
| JP2011518125A5 (https=) | ||
| JP2010516229A5 (https=) | ||
| JP2014520088A5 (https=) | ||
| JP2020500834A5 (https=) | ||
| JP2022525377A5 (https=) | ||
| JP2010520290A5 (https=) | ||
| EP3337506B1 (en) | Combinations and uses thereof | |
| JP2021501579A5 (https=) | ||
| JP2022512905A5 (https=) | ||
| JPWO2023026791A5 (https=) | ||
| JP2021511024A5 (https=) | ||
| JP2024507948A5 (https=) | ||
| JP2013521252A5 (https=) | ||
| JP2020533382A5 (https=) |